Online citations, reference lists, and bibliographies.

Medicinal Inorganic Chemistry: Metal‐containing Diagnostic Compounds

K. Thompson
Published 2011 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Metallopharmaceuticals designed for use in diagnostic compounds cover a broad spectrum of diagnostic modalities, starting with barium sulfate for enhanced X-ray contrast, to the hugely successful gadolinium-based magnetic resonance imaging (MRI) contrast agents, to more recent advances in positron emission tomography (PET) and single photon emission computed tomography (SPECT) requiring radiolabeled metal-based diagnostic agents for image detection. In each case, the pharmacokinetics of tissue distribution and the thermodynamic stability of the metal-ligand coordination complex are very important to the clinical utility of the particular compound. For radiolabeling, the speed and ease of radiolabel production are also key features of the metallodiagnostic agent's utility. Keywords: MRI; contrast agent; SPECT; PET; rubidium; gadolinium; 64Cu; 68Ga; 67Ga; 18F; 99mTc; bifunctional metallopharmaceutical
This paper references
10.1039/b819098d
A lysine walk to high relaxivity collagen-targeted MRI contrast agents.
P. Caravan (2009)
10.1021/JA065264L
A smart magnetic resonance contrast agent for selective copper sensing.
E. L. Que (2006)
10.1002/anie.200800212
High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging.
Eric J. Werner (2008)
10.1021/JA0103647
pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation.
M. P. Lowe (2001)
10.1039/b717390c
A benzene-core trinuclear GdIII complex: towards the optimization of relaxivity for MRI contrast agent applications at high magnetic field.
J. B. Livramento (2008)
10.1007/3-540-45733-X_3
Relaxivity of MRI Contrast Agents
É. Tóth (2002)
10.1007/3-540-45733-X_5
New Classes of MRI Contrast Agents
Vincent Jacques (2002)
10.1002/ANIE.200502245
Multilocus binding increases the relaxivity of protein-bound MRI contrast agents.
Z. Zhang (2005)
10.1002/1522-2594(200009)44:3<433::AID-MRM14>3.0.CO;2-9
Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles
S. Anderson (2000)
10.1021/JA017168K
The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates.
P. Caravan (2002)
10.1039/A827019Z
Lanthanide(III) chelates for NMR biomedical applications
S. Aime (1998)
10.1039/B514859F
Design of targeting ligands in medicinal inorganic chemistry.
T. Storr (2006)
10.1021/IC0200390
Mechanistic studies of a calcium-dependent MRI contrast agent.
W. Li (2002)
10.1021/CR980451Q
Radiometal-Labeled Agents (Non-Technetium) for Diagnostic Imaging
C. Anderson (1999)
10.1021/BC700230M
Water-soluble contrast agents targeted at the estrogen receptor for molecular magnetic resonance imaging.
C. Gunanathan (2007)
10.1021/BC049817Y
Next generation, high relaxivity gadolinium MRI agents.
K. Raymond (2005)
10.1016/0002-9149(91)90456-U
Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease.
R. Stewart (1991)
10.1021/IC049028S
Gadolinium(III) 1,2-hydroxypyridonate-based complexes: toward MRI contrast agents of high relaxivity.
J. Xu (2004)
10.1097/RLI.0b013e3181852171
Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C
T. Frenzel (2008)
10.1007/s00259-007-0603-2
Determinants of the response of left ventricular ejection fraction to vasodilator stress in electrocardiographically gated 82rubidium myocardial perfusion PET
T. Brown (2007)
10.1021/IC700686K
Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent.
P. Caravan (2007)
10.1021/bc8002919
Cell-permeable MR contrast agents with increased intracellular retention.
Paul J H Endres (2008)
10.1038/73780
In vivo visualization of gene expression using magnetic resonance imaging
A. Louie (2000)
10.2174/157488608783333989
Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis.
M. Perazella (2008)
10.1039/B313872K
Radiohalogens for imaging and therapy.
M. Adam (2005)
10.1039/B705989B
Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.
A. Vāvere (2007)
10.1021/ja800834y
EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.
Kirsten Overoye-Chan (2008)
10.1021/JM000983A
[GdPCP2A(H2O)2]-: A Paramagnetic Contrast Agent Designed for Improved Applications in Magnetic Resonance Imaging
S. Aime (2000)
10.1016/S0730-725X(03)00081-X
An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis.
M. E. Bartolini (2003)
10.1007/s00775-007-0265-3
Multimodal MRI contrast agents
Luca Frullano (2007)
10.1021/IC0702926
Potentiometric and relaxometric properties of a gadolinium-based MRI contrast agent for sensing tissue pH.
Ferenc K Kálmán (2007)
10.1021/IC026240S
Toward optimized high-relaxivity MRI agents: the effect of ligand basicity on the thermodynamic stability of hexadentate hydroxypyridonate/catecholate gadolinium(III) complexes.
D. M. Doble (2003)
10.1016/S0010-8545(02)00100-5
Biomedical uses and applications of inorganic chemistry. An overview
Nicholas Farrell (2002)
10.1007/s00259-002-0900-8
Current use and future potential of organometallic radiopharmaceuticals
R. Schibli (2002)
10.1021/ic00299a011
Solution structure and dynamics of lanthanide(III) complexes of diethylenetriaminepentaacetate: a two-dimensional NMR analysis
B. Jenkins (1988)
10.1021/BC060269T
Use of lanthanide-grafted inorganic nanoparticles as effective contrast agents for cellular uptake imaging.
P. Voisin (2007)
10.1021/cr0782426
Molecular imaging with PET.
S. Ametamey (2008)
10.1021/JM061324M
Toward improved syntheses of dendrimer-based magnetic resonance imaging contrast agents: new bifunctional diethylenetriaminepentaacetic acid ligands and nonaqueous conjugation chemistry.
H. Xu (2007)
10.1021/JA00132A025
Gadolinium complex of tris[(3-hydroxy-1-methyl- 2-oxo-1,2-didehydropyridine-4-carboxamido)ethyl]-amine: A New Class of gadolinium magnetic resonance relaxation agents
J. Xu (1995)
10.1016/j.nucmedbio.2008.10.010
Synthesis and biodistribution of lipophilic and monocationic gallium radiopharmaceuticals derived from N,N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine: potential agents for PET myocardial imaging with 68Ga.
Yui-May Hsiao (2009)
10.1039/b719704g
Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes.
P. Hermann (2008)
10.1039/B510982P
Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.
P. Caravan (2006)
10.1021/IC0493447
Toward optimized high-relaxivity MRI agents: thermodynamic selectivity of hydroxypyridonate/catecholate ligands.
V. C. Pierre (2004)
10.1039/A827043Z
The biomedical chemistry of technetium and rhenium
J. R. Dilworth (1998)
10.1007/s00775-007-0215-0
A new bisphosphonate-containing 99mTc(I) tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation
E. Palma (2007)
10.1021/ar800245h
Bioresponsive, cell-penetrating, and multimeric MR contrast agents.
Jody L. Major (2009)
10.1021/JA012668Z
An unusual dimeric structure of a Cu(I) bis(thiosemicarbazone) complex: implications for the mechanism of hypoxic selectivity of the Cu(II) derivatives.
A. Cowley (2002)
10.1021/IC0261575
The effect of ligand scaffold size on the stability of tripodal hydroxypyridonate gadolinium complexes.
B. O'sullivan (2003)
10.1038/242190a0
Image Formation by Induced Local Interactions: Examples Employing Nuclear Magnetic Resonance
P. Lauterbur (1973)
10.1021/AR0400894
Benefiting from the unique properties of lanthanide ions.
Jean-Claude G Bünzli (2006)
10.1021/BC000070V
Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals.
S. Liu (2001)
10.1073/PNAS.93.13.6610
Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI.
S. Young (1996)
10.1002/ANIE.200700700
Collagen-targeted MRI contrast agent for molecular imaging of fibrosis.
P. Caravan (2007)
10.1021/cr00081a003
Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design
R. Lauffer (1987)
10.1021/CR980436L
99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.
S. Liu (1999)
10.1021/ic702440e
Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. insights into mechanisms of copper uptake and hypoxia selectivity.
Z. Xiao (2008)
10.1016/S0006-2952(99)00314-7
Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy.
J. Sessler (2000)
10.1002/(SICI)1521-3773(19990601)38:11<1512::AID-ANIE1512>3.0.CO;2-Y
Metals in Medicine.
Zijian Guo (1999)
10.1021/IC000563B
Syntheses and relaxation properties of mixed gadolinium hydroxypyridinonate MRI contrast agents.
S. Cohen (2000)
10.1002/ANIE.200462400
All Science Is Interdisciplinary—From Magnetic Moments to Molecules to Men (Nobel Lecture)
Paul C. Lauterbur (2005)
10.1002/jmri.10180
Insights into the use of paramagnetic Gd(III) complexes in MR‐molecular imaging investigations
S. Aime (2002)
10.1021/cr00019a013
Coordination compounds in nuclear medicine
S. Jurisson (1993)
10.1016/0730-725X(90)90055-7
The relationship between thermodynamics and the toxicity of gadolinium complexes.
W. Cacheris (1990)
10.1021/ic801730u
1,2-hydroxypyridonate/terephthalamide complexes of gadolinium(III): synthesis, stability, relaxivity, and water exchange properties.
Eric J. Werner (2009)
10.1039/b809365b
99m-Technetium carbohydrate conjugates as potential agents in molecular imaging.
M. Bowen (2008)
10.1021/CR980440X
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications.
P. Caravan (1999)
10.1039/B416256K
Metal complexes of maltol and close analogues in medicinal inorganic chemistry.
K. Thompson (2006)
10.2310/7290.2006.00026
Quantitative Imaging of Cell-Permeable Magnetic Resonance Contrast Agents Using X-Ray Fluorescence
Paul J H Endres (2006)
10.1016/j.conb.2003.09.009
New magnetic resonance contrast agents as biochemical reporters
T. Meade (2003)
10.1021/cr900325h
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.
T. Wadas (2010)
10.1016/0730-725X(92)90016-S
Dissociation of gadolinium chelates in mice: relationship to chemical characteristics.
P. Wedeking (1992)
10.1039/B416040A
A glucosamine-dipicolylamine conjugate of 99mTc(I) and 186Re(I) for use in imaging and therapy.
T. Storr (2005)
10.1021/CR980435T
Potential technetium small molecule radiopharmaceuticals.
S. Jurisson (1999)
10.1021/bc700471z
99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer.
Jiyun Shi (2008)
10.1021/BC0499681
Carbohydrate conjugates for molecular imaging and radiotherapy: 99mTc(I) and 186Re(I) tricarbonyl complexes of N-(2'-Hydroxybenzyl)-2-amino-2-deoxy-D-glucose.
S. Bayly (2004)
10.1021/JA057954F
Tris(pyrone) chelates of Gd(III) as high solubility MRI-CA.
D. Puerta (2006)
10.1021/CR980441P
Metal-Based X-ray Contrast Media.
S. Yu. (1999)



Semantic Scholar Logo Some data provided by SemanticScholar